Company / R&D Expense
IRONWOOD PHARMACEUTICALS INC R&D Expense History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D Expense
$95.1M
FY2025
5-year range
$44.3M / $116.1M
FY2021-FY2025
Trend
+114.9%
vs FY2024
Sector context
#146 of 210
Health Care
What the data says
At $95M, IRONWOOD PHARMACEUTICALS INC's r&d expense ranks #146 of 210 in the Health Care sector. R&D Expense has fluctuated over the past 10 years, ranging from $44M in FY2024 to $139M in FY2018.
Based on SEC 10-K filings.
$95M in FY2025 with a 5-year CAGR of -1.2%.
Declined from $116M to $95M over the past 2 years.
Health Care sector context is included.
R&D Expense over time
Growth rates
- 3-Year CAGR
- +2.6%
- 5-Year CAGR
- -1.2%
- 10-Year CAGR
- -
Sector benchmark
#146 of 210 in Health CareTop 70% of 210This company $95.1M Sector average $644.0M
▼
-85.2% below sector average
Key checks
Key Insights
- 5-year CAGR of -1.2%, indicating a declining trend.
- In FY2025, r&d expense increased 114.9% year-over-year.
- Ranks #146 out of 210 companies in the Health Care sector.
- Peak r&d expense was recorded in FY2018.
Company context
Key Data Points
- Altman Z-Score -2.17 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $95.1M | +114.9% |
| FY2024 | $44.3M | -61.9% |
| FY2023 | $116.1M | +31.8% |
| FY2022 | $88.1M | +25.1% |
| FY2021 | $70.4M | -30.3% |
| FY2020 | $101.1M | -12.2% |
| FY2019 | $115.0M | -17.5% |
| FY2018 | $139.5M | +58.3% |
| FY2017 | $88.1M | -36.8% |
| FY2016 | $139.5M | +28.3% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026